John G. Freund, M.D. founded Skyline Ventures, in October 1997 and served as a Managing Director of Skyline until 2023. Prior to joining Skyline, Dr. Freund served as Managing Director in the private equity group of Chancellor Capital Management. In November 1995, he co-founded Intuitive Surgical, Inc., and served on its board of directors until March 2000. In 1996, he co-founded Arixa Pharmaceuticals, Inc., and served as its CEO until it was acquired by Pfizer in October 2020. From 1988 to 1994, he held various positions at Acuson Corporation, a maker of ultrasound equipment that is now part of Siemens, most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988, he was at Morgan Stanley & Co., where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. He serves on the board of directors of Collegium Pharmaceuticals, Inc., Sutro Biopharma, Inc., and SI-Bone, an orthopedic device company. He also serves on the boards of directors of fourteen U.S. registered investment funds managed by affiliates of Capital Group, Inc. He previously served on the boards of directors of Map Pharmaceuticals, Inc., MAKO Surgical Corp., Proteon Therapeutics, Inc., Tetraphase Pharmaceuticals, Inc., Concert Pharmaceuticals, Inc., and was Chairman of XenoPort, Inc. He is a member of the Advisory Board for the Harvard Business School Healthcare Initiative.
Dr. Freund received a B.A. in History from Harvard College, an M.D. from Harvard Medical School, and an M.B.A. from Harvard Business School, where he was a Baker Scholar.